Bernstein Sticks to Their Hold Rating for Pfizer (PFE)
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $32.00. The ...
The Pharma Letter3h
Samsung Bioepis and Teva link up on Soliris biosimilar in USA
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...
PipelineReview.com4h
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...
Armed robbery in Revesby6h
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioWorld19h
Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
The CEOs Who Are Tearing Up the Policies Trump Hates
Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; ‘EVERYBODY WANTS TO BE MY FRIEND!!!’ ...
MedPage Today23h
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...